Combination Uricosuric Therapy for Refractory Hyperuricemia on High‑Dose Febuxostat

Indications for Adding a Uricosuric Agent

In patients receiving the maximum international dose of febuxostat (120 mg daily) who have adequate renal function (eGFR > 50 mL/min) and no history of kidney stones, adding a uricosuric medication (e.g., probenecid, fenofibrate, or losartan) is recommended rather than switching to a different urate‑lowering drug. 1
Probenecid 500 mg once or twice daily, titrated upward, should be used to achieve a target serum uric acid < 6 mg/dL (≈360 µmol/L). This dual‑mechanism approach combines reduced uric acid production (febuxostat) with enhanced renal excretion (probenecid). 1
Fenofibrate or losartan may be selected as alternative uricosurics when the patient has comorbid hyperlipidemia or hypertension, respectively. [2][1]

Uricosuric agents should not be added in patients with an estimated glomerular filtration rate < 50 mL/min. 2
A prior history of kidney stones or moderate‑to‑severe chronic kidney disease also precludes the use of uricosurics. 2

The standard lifelong goal for most patients is serum uric acid < 6 mg/dL (≈360 µmol/L). 2
For individuals with severe disease (e.g., tophi or chronic arthropathy), a more stringent target of < 5 mg/dL (≈300 µmol/L) is advised until crystal dissolution is complete, after which the goal reverts to < 6 mg/dL. 2
When baseline serum uric acid is markedly above target (e.g., > 8 mg/dL), escalation with combination therapy is indicated. 2

Switching to allopurinol (starting at 100 mg/day and titrating up to a maximum of 800 mg/day) is an option when febuxostat plus a uricosuric does not achieve target uric acid levels. [2][1]
Pegloticase may be considered for patients with severe refractory gout, extensive tophi, and poor quality of life after all oral options at maximal doses have been exhausted. [2][1]

Serum uric acid should be measured every 2–5 weeks during titration of the added uricosuric agent to guide dose adjustments. 1
Once the target level is reached, monitoring can be spaced to every 6 months to assess adherence and detect potential flares. 1

The recommendations above are derived from the American College of Rheumatology (ACR) gout management guidelines, which grade these statements as moderate‑quality evidence based on randomized trials and expert consensus. [1][2]

The American College of Rheumatology recommends verifying adequate dosing and adherence to xanthine oxidase inhibitors before considering treatment failure, as most patients require doses above commonly prescribed levels to achieve target serum uric acid <6 mg/dL 3
The maximum FDA-approved dose of allopurinol is 800 mg/day, and febuxostat is 80 mg/day, with the 80 mg dose achieving target serum uric acid <6 mg/dL in 67% of patients 3

The American College of Rheumatology suggests adding probenecid as combination therapy to xanthine oxidase inhibitors, rather than switching agents, if both inhibitors were appropriately dosed to maximum levels and the patient has adequate renal function (eGFR >50 mL/min) 3, 4
Probenecid can be added to febuxostat at 500 mg once or twice daily, then titrated upward to achieve target serum uric acid <6 mg/dL, addressing hyperuricemia through dual mechanisms: reduced uric acid production and increased renal excretion 3, 4

Uricosuric agents are contraindicated if eGFR <50 mL/min, history of kidney stones, or moderate-to-severe CKD, due to increased risk of adverse effects 3, 5

The standard target serum uric acid level is <6 mg/dL for all patients with gout, maintained lifelong, with monitoring every 2-5 weeks during dose titration, then every 6 months once target achieved 3, 4, 5
An aggressive target of <5 mg/dL may be considered for patients with severe disease burden to facilitate faster crystal dissolution 4